BOLD - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים Boundless Bio Inc

Boundless Bio, Inc. (BOLD) is a recognized leader in developing targeted DNA drugs for the therapy of complex oncological diseases. The scaling potential here is immense: a unified technological base allows for the launch of a series of high-margin products. Operating revenue dynamics YoY (TTM) confirm current growth rates, where 0.00 reflects the latest metric value. However, early-stage trials and a high burn rate create significant financial risks.

This indicator assesses business expansion rates by comparing current trailing twelve-month (TTM) revenue with the same period from the previous cycle. Analyzing the TTM sales volume change allows for the identification of demand stability while excluding random operational fluctuations. The calculation is based on the percentage difference in total revenues over a twelve-month interval. For Boundless Bio, Inc. (BOLD), growth in this metric would signify a successful market entry. The key driver will be the commercialization of innovative drugs targeting ecDNA in oncology therapy.